**
Documents obtained through a Freedom of Information Act request have revealed troubling connections between the Trump administration and Bayer, the multinational corporation facing extensive litigation over its glyphosate-based herbicides. In a meeting held on 17 June 2025, key officials from the Environmental Protection Agency (EPA) engaged in discussions with Bayer’s CEO, Bill Anderson, and other executives regarding the ongoing legal battles surrounding glyphosate, just months before the administration took steps to bolster Bayer’s standing in court.
The Meeting’s Context
As Bayer grappled with thousands of lawsuits claiming that its glyphosate products, most notably Roundup, contributed to cancer diagnoses, the 17 June meeting at the EPA signalled a significant moment in the company’s legal strategy. The internal records indicate that the meeting was not just a routine regulatory discussion; it was a concerted effort to address litigation challenges, specifically “supreme court action” regarding the company’s liability for cancer risks associated with its products.
At the heart of the lawsuits are allegations that Bayer did not adequately warn consumers about the potential dangers of glyphosate. Research has persistently pointed to a link between glyphosate and various forms of cancer, raising urgent questions about the safety of these widely used herbicides.
The Administration’s Support for Bayer
Following the meeting, the Trump administration’s actions have seemingly favoured Bayer, culminating in a series of legal maneuvers that support the company’s interests. On 1 December 2025, the solicitor general appointed by Trump, D. John Sauer, urged the Supreme Court to hear Bayer’s case, which the court subsequently agreed to, setting a date for hearings on 27 April 2026.
Moreover, the White House invoked the Defense Production Act on 18 February 2026, ensuring the continued production of glyphosate and providing a form of immunity to Bayer and other manufacturers. A further amicus brief filed by Sauer on 2 March demonstrated the administration’s unwavering support for Bayer’s position.
Critics of this alignment argue that it exemplifies a concerning trend where the interests of major corporations override public health considerations. Nathan Donley, an environmental health scientist with the Center for Biological Diversity, expressed dismay, stating, “It’s becoming abundantly clear that the political appointees at the EPA are more invested in protecting pesticide company profits than the health of Americans.”
Industry Influence and Public Health
The implications of this meeting and the resulting actions raise critical questions about the influence of corporate interests on regulatory bodies. Critics like attorney Whitney Di Bona have highlighted the disparity in access to the EPA, suggesting that while Bayer’s executives can engage directly with top officials, the voices of individuals harmed by glyphosate remain unheard.
Naomi Oreskes, a professor at Harvard, noted that the meeting exemplifies a troubling pattern of corporate influence in regulatory decision-making. “This kind of access is not extended to the public, particularly to those who have suffered due to these products,” she stated, emphasising the need for equitable representation in discussions affecting public health.
Zen Honeycutt, founder of Moms Across America, echoed these sentiments, reflecting on the ongoing struggle for accountability and transparency within the EPA. “Coercion by chemical companies on our regulatory agencies is nothing new,” she remarked, underscoring the uphill battle faced by advocacy groups seeking to protect public health.
Why it Matters
The revelations surrounding the Trump administration’s interactions with Bayer illuminate a significant and troubling intersection of corporate power and public health policy. As regulatory agencies increasingly align with the interests of powerful corporations, the health of millions hangs in the balance. The ongoing litigation surrounding glyphosate not only raises critical questions about product safety but also highlights the urgent need for regulatory reforms that prioritise public well-being over corporate profits. This case serves as a reminder that the fight for safe and transparent regulation is far from over, and it demands the attention and action of concerned citizens and policymakers alike.
